国产九价HPV疫苗上海首针开打，每针499元惠及9至45岁女性

Core Viewpoint - The launch of China's first domestically produced nine-valent HPV vaccine marks a significant advancement in cervical cancer prevention for women aged 9 to 45 in Shanghai, providing a new option for vaccination [1][3]. Group 1: Vaccine Details - The nine-valent HPV vaccine is priced at 499 yuan per dose, totaling 506.5 yuan including service fees in Shanghai [1]. - The vaccination schedule for women aged 9 to 17 consists of two doses administered at 0 and 6 months, with a total cost of approximately 1013 yuan; for women aged 18 to 45, a three-dose schedule is followed at 0, 1, and 6 months, costing around 1519.5 yuan [1]. - The vaccine has been fully launched in Shanghai, with initial doses being distributed to community health service centers, and citizens can make appointments through a health app or by contacting local centers [1]. Group 2: Clinical Research and Safety - The vaccine underwent 18 years of research, involving over one million independent tests and multiple clinical studies, with about 11,000 healthy female volunteers participating in trials since 2019 [4][7]. - The adverse reaction rate during clinical trials was low, primarily consisting of mild to moderate local reactions that typically resolved quickly, indicating good overall safety [7]. - The vaccine provides protection against nine HPV types associated with cervical cancer, demonstrating comparable immune response levels to existing products in clinical studies published in a reputable medical journal [4][7]. Group 3: Market Impact and Accessibility - The vaccine has received approval from the National Medical Products Administration, supported by robust clinical data on safety and efficacy [9]. - The affordable pricing strategy is expected to enhance accessibility for eligible women, promoting higher vaccination rates and contributing positively to cervical cancer prevention efforts [9].